Home | Log In | Register | Our Services | My Account | Contact | Help |
Come along to one of our well know Shares Investor Evenings where you will have the chance to listen and talk to directors of dynamic listed companies. At this event on 23 March we have Directors from Sound Energy, Sphere Medical and Valirx.
- Listen to Directors present their latest plans regarding development and growth of their business
- Talk directly to the companies, get to know the Directors and personally put forward your questions
- Network with other attendees including private investors, wealth managers, fund managers and financial institutions over drinks and canapés
The evening exposes investors to companies and funds across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Thursday 23rd March 2017
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:18.00 | Registration and coffee | |
18.30 | Presentations • James Parsons, CEO - Sound Energy (SOU) • Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR) • Dr. George Morris, Chief Operations Officer - Valirx (VAL) + More to be announced | |
20.30 | Drinks reception and canapés | |
21.30 | Close |
![]() | Sound Energy is a well-funded African and European upstream gas company, listed on AIM, with a recent significant discovery in Morocco, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and a potentially transformational drill programme. We are pursuing an onshore gas strategy underpinned by strong European gas fundamentals, which is proving very robust to the current oil price environment and to an increasingly carbon-conscious world (where gas is, rightly, seen as a cleaner alternative to coal and oil). |
![]() | Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs. |
![]() | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |